LLY - Lilly Incyte's second baricitinib study shows improvement in hair regrowth in alopecia areata patients

Eli Lilly (LLY) and Incyte (INCY) announce results from a second Phase 3 trial (BRAVE-AA1) evaluating the efficacy and safety of once-daily baricitinib 2-mg and 4-mg in adults with severe alopecia areata ((AA)).The data are consistent with findings from the first Phase 3 clinical trial, BRAVE-AA2, top-lined earlier this year.Results of BRAVE-AA1 showed that at?Week 36,?the proportion of patients reaching 80% or more scalp hair coverage?was?achieved?by 35% (p?0.001) of patients treated with baricitinib 4-mg/day, 22% (p?0.001) of patients treated with?baricitinib?2-mg/day and? 5% of patients in the placebo group, meeting the primary endpoint.BRAVE-AA2 showed that at Week 36 primary endpoint was achieved by 33% of patients treated with?baricitinib?4-mg/day, 17% of patients treated with baricitinib 2-mg/day and 3% in the placebo group.The most common adverse events in both studies included upper respiratory tract infections, headache and acne. No deaths or venous thromboembolic events were reported.The safety profile of baricitinib in the two studies was consistent with its known

For further details see:

Lilly, Incyte's second baricitinib study shows improvement in hair regrowth in alopecia areata patients